Back to Journals » Biologics: Targets and Therapy » Volume 14

An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis

Authors Chimenti MS, D'Antonio A, Conigliaro P, Ferrigno S, Vendola A, Ferraioli M, Triggianese P, Costa L, Caso F, Perricone R

Received 30 April 2020

Accepted for publication 5 August 2020

Published 20 August 2020 Volume 2020:14 Pages 53—75

DOI https://doi.org/10.2147/BTT.S260754

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Editor who approved publication: Professor Shein-Chung Chow


Maria Sole Chimenti,1,* Arianna D’Antonio,1,* Paola Conigliaro,1 Sara Ferrigno,1 Andrea Vendola,1 Mario Ferraioli,1 Paola Triggianese,1 Luisa Costa,2 Francesco Caso,2 Roberto Perricone1

1Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy; 2Rheumatology Unit, Department of Clinical Medicine and Surgery, School of Medicine and Surgery, University Federico II, Naples, Italy

*These authors contributed equally to this work

Correspondence: Maria Sole Chimenti Tel +39 06 20900358
Email maria.sole.chimenti@uniroma2.it

Abstract: Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy typically associated with psoriasis (PsO). The pathogenesis is strictly related to the association among the presence of genetic risk alleles and innate and acquired immune response with dramatic consequences on bone remodeling. Clinically, PsA patients may present heterogenicity of articular and periarticular manifestations that may be associated with the presence of comorbidities making treatment decision challenging in patients management. The identification of patient-targeted therapies is still a critical issue. Actually, several biological and synthetic drugs are promising in terms of efficacy and safety profile. National and international treatment recommendations support clinicians in the decision of the best treatment, although they may have limits basically related to updates and different outcomes included in the clinical studies evaluated. The aim of this narrative review is therefore to give guidance for clinicians for PsA patients treatment. For this purpose, we evaluated evidence on biological therapies efficacy used for PsA treatment. Specifically, we reviewed data on biological therapies, Janus kinases (JAK) inhibitors, and drugs with a new mechanism of action that are part of the treatment pipeline. The concept of “switching” and “swapping” is also described, as well as data concerning special populations such as pregnant women and elderly patients.

Keywords: psoriatic arthritis, biological therapies, TNF-inhibitors, JAK-inhibitors, phosphodiesterase-4, tofacitinib, tsDMARDs

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]